Course of coronary heart disease in patients with cardiovascular renal metabolic syndrome and separately metabolic

Introduction. Renal dysfunction is increasingly recognized as a key mediator of the association between metabolic risk factors and cardiovascular disease (CVD). Therefore, rather than simply viewing cardiorenal (CR) syndrome and cardiometabolic (CM) diseases as separate conditions, it is clear that we need to consider them as the broader concept of cardiovascular-renal-metabolic syndrome (CVMS). Purpose of the study: Studying the differences in the influence of SSMPS and separately metabolic (MS) on the course of coronary heart disease (CHD).
Materials and methods. The study included 116 patients - 69 (59.5 %) men and 47 (40.5 %) women who were treated at the RCH Hospital No. 2 from 2022 to 2023. The patients were divided into two groups, the 1st group included n = 52 with cardiovascular-renal-metabolic syndrome, the 2nd group included n = 64 with metabolic syndrome. The duration of the study is 18 months.
Results. Primary indicators of low-density lipoproteins (LDL) in the 1st group were 2.9 ± 3.6 in the 2nd group 2.6 ± 4.0 p < 0.05, and upon re-examination, the ratio of values was as follows - 3 .2 ± 2.8 to 3.0 ± 3.3 p > 0.05. Patients with type 2 diabetes mellitus (DM2) increased by the end of the examination in both groups, but not so significantly in relation to the total weight of 2.6 % to 3.4 % p < 0.05. During the repeated examination, the indicators of arterial hypertension (AH) of the 2nd degree prevailed (34.6 % to 32.8 %) p < 0.05, and there was also an increase in patients with hypertension of the 3rd degree (25.0 to 25.0) p < 0.05, mainly due to patients of the 1st group with kidney disease. Re-admission to the hospital occurred more often in patients with SSPMS than in the group with MS 9.5 ± 7.2 and 12.6 ± 6.8 months, p < 0.05. In-hospital mortality from acute myocardial infarction (AMI) slightly prevailed in group 1 upon re-admission to hospital, ratio n = 3 (5.8 %), in group 2 n = 1 (1.6 %), p > 0.05.
Conclusions. In conclusion, our nonrandomized prospective study showed that patients with cardiovascular-renal-metabolic syndrome are at a higher risk of developing cardiovascular events than patients with metabolic syndrome alone. Analysis of lipid metabolism in the group of cardiovascular-renal-metabolic syndrome showed that in a short time after discharge from the hospital, from 6 months to 1.5 years, the indicators of total cholesterol, triglycerides and lowdensity lipoproteins progress negatively to the time of relapse of angina pectoris.

1. Kuschnir MCC, Bloch KV, Szklo M, et al. ERICA: prevalence of metabolic syndrome in Brazilian adolescents. Revista de saúde Pública. 2018;50(11):256-268. https://doi.org/10.1590/S01518-8787.2016050006701

2. Xiang Y, Zhou W, Duan X, et al. Metabolic Syndrome, and Particularly the Hypertriglyceridemic-Waist Phenotype, Increases Breast Cancer Risk, and Adiponectin Is a Potential Mechanism: A Case-Control Study in Chinese Women. Front Endocrinol (Lausanne). 2020;10:905. https://doi.org/10.3389/fendo.2019.00905

3. Grgurevic I, Podrug K, Mikolasevic I, et al. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol. 2020;2020:1-10. https://doi.org/10.1155/2020/9181368

4. Ivanova N, Liu Q, Agca C, et al. White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer’s disease rat model. J Neuroinflammation. 2020;17(1):29. https://doi.org/10.1186/s12974-020-1698-7

5. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:e840–e878. https://doi.org/10.1161/CIR.0000000000000664

6. Burrows NR, Koyama A, Pavkov ME. reported cases of end-stage kidney disease–United States, 2000-2019. MMWR Morb Mortal Wkly Rep. 2022;71:412–415. https://doi.org/10.15585/mmwr.mm7111a3

7. Takashi Kadowaki MD, Hiroshi Maegawa MD, Hirotaka Watada MD, Daisuke Yabe MD, Koichi Node MD, Toyoaki Murohara MD, Jun Wada MD. Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. Journal Diabetes, Obesity and Metabolism. 2022;24:2283–2296. https://doi.org/ 10.1111/dom.14829

8. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Després J-P, et al; on behalf of the American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023; 148:1636-1664. https://doi.org/10.1161/CIR.0000000000001186

9. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, et al. on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:840–878. https://doi.org/10.1161/CIR.0000000000000664

10. Koenen M, Hill MA, Cohen P, Sowers JR. Obesity, adipose tissue and vascular dysfunction. Circ Res. 2021;128:951–968. https://doi.org/10.1161/CIRCRESAHA.121.318093

11. Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. JACC Heart Fail. 2021;9:100–111. https://doi.org/10.1016/j.jchf.2020.09.006

12. Hicks CW, Yang C, Ndumele CE, Folsom AR, Heiss G, Black JH, Selvin E, Matsushita K. Associations of obesity with incident hospitalization related to peripheral artery disease and critical limb ischemia in the ARIC study. J Am Heart Assoc. 2018;7:e008644. https://doi.org/10.1161/JAHA.118.008644

13. Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, et al; on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984–e1010. https://doi.org/10.1161/CIR.0000000000000973

14. Lee M-K, Han K, Kim MK, et al. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study. Sci Rep. 2020;10(1):2313. https://doi.org/10.1038/s41598-020-59203-z

15. Efremova O. A., Kamyshnikova L. A., Nikitin A.М. Parallels of lipid metabolism and hyperhomocysteinemia in patients with ischemic heart disease and metabolic syndrome. Scientific result. Series Medicine and Pharmacy. 2018;1(1):12-19. (In Russ). https://doi.org/10.18413/2313-8955-2014-1-1-48-52

16. Kytikova O.Yu., Antonyuk M.V., Gvozdenko T.A., Novgorodtseva T.P. Metabolic aspects of the relationship between asthma and obesity. Obesity and metabolism. 2019;15(4):9-14. (In Russ). https://doi.org/10.14341/omet9578